Article

New Liquid Formulation Speeds Cancer Therapy Administration

A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.

A new liquid drug formulation from Teva Pharmaceutical Industries Ltd. will allow some cancer patients to see their therapy administered faster.

Teva’s bendamustine hydrochloride (Treanda) injections treat patients with chronic lymphocytic leukemia or indolent B-cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen, according to a company press release.

Preparation time will be reduced for health care professionals with the drug’s new liquid formulation, which removes the step of reconstituting lyophilized powder with sterile water prior to adding the dose of medicine to the infusion bag and administering it to a patient.

“With the new liquid formulation of Treanda, we are not only building on the legacy of this important product, but also furthering Teva’s commitment to continuously improving our medicines,” said Paul Rittman, vice president and general manager of Teva Oncology, in a press release.

The most common side effects associated with Treanda included nausea, fatigue, vomiting, diarrhea, fever, and weight loss.

Related Videos
Image Credit: © Birdland - stock.adobe.com
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC